Halozyme obtains $5.5 million payment from Baxter
The transaction represents the final prepaid product-based payment due under the terms of its Hylenex licensing agreement, which provides Baxter with exclusive distribution rights. The payment has been
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.